events

HUM-MOLGEN -> Events -> Meetings and Conferences

Search

14th Annual Drug Discovery Leaders’ Summit

February 04, 2013

Oxford Global Conferences, Geneva, Switzerland 10th&11th June 2013 Agenda Innovation Driven Discovery Day 1 Stream 1 – R&D Models For The Future • Open innovation • Collaborative models • Virtual R&D • Public/Private partnerships • Mergers & acquisitions • New models for lead generation Day 1 Stream 2 – Screening & Assays: Enabling Technologies • RNAi screening • Integrated lead discovery • Phenotypic screening • FBS-by-biochemical assays • Continuous hit finding • Assays for anti-viral research Day 2 Stream 1 – Innovative Drug Targets • Novel biological targets • Promising targets for neurology • Fragment-based approaches for difficult targets • Purinome-targeted oncology libraries • Target identification in endocrinology • GPCR signalling pathways Day 2 Stream 2 – Supporting Innovation: Data & Information Management • Using multifactorial data to improve compound survival • Data mining and analysis • Omics data integration • Sharing & consolidating information • Managing complex discovery portfolios Discovery Chemistry & Drug Design Day 1 Stream 3 – Discovery Chemistry: Latest Case Studies • Hit to lead optimisation • Structure-activity relationships • Optimising allosteric kinase inhibitors • Fragment based drug discovery • Combinatorial and high-throughput chemistry Drug Design: Novel Approaches • Structure based drug design • Anti-target modelling • Protein-ligand interactions • Antibodies as discovery tools • Innovation in IPS cell research • Advances in polypharmacology & in silico profiling

Organized by:			Oxford Global Conferences
Invited Speakers:			Alexander Alanine Head, Chemistry Technologies & Innovation, Roche Daniel Baeschlin Director Compound Management, Novartis Karl-Heinz Baringhaus Head of Structure, Design & Informatics, Sanofi Aventis Ulrich Betz, Director, Department Head Innovation & Entrepreneurship Incubator, Merck Serono Markus Boehringer Head of External Innovation & Alliances Metabolic Diseases, Roche Francoise Bono Research Director, Sanofi Michael Braxenthaler Pharma Research and Early Development Informatics - Global Head Strategic Alliances, Roche Sergio Cantoreggi CSO, Helsinn Healthcare SA Philippe Couttet Head Pathway Integration, Discovery and Investigative Safety, Novartis Emilio Diez, VP Molecular Discovery Research, GSK José Duca Head, Computer-Aided Drug Discovery, Novartis Vic E. Myer Executive Director, Developmental and Molecular Pathways, Novartis Ivan Efremov Senior Principal Scientist, Pfizer David Elder Director Scinovo, GSK R&D Eduard Felder Director, Chemical Core Technologies, Nerviano Medical Sciences Tina Flatau, VP Alliances and Project Management, Prosensa Matthias Frech, Head of Molecular Interactions & Biophysics, Merck Joachim Freubis Executive Director, Pfizer Pascal Furet Research Director, Novartis Paul Germann, Vice President New Frontier Science Europe, Takeda Adrian Gill Head of Medicinal Chemistry , CVGI, AstraZeneca Johannes Grosse Head of Discovery Biology, Takeda Peter Hamley Global Head, Parallel Synthesis & Natural Products, Lead Generation to Candidate Realisation, Sanofi R&D Juergen Hammer Global Head Disease and Translational Informatics, Roche Robert Hayes, Vice President and Venture Leader, Centyrex Venture, Janssen R&D Marius Hoener Senior Principal Scientist, Drug Discovery Project Team Leader, Vice Director, Roche (Stream Chair) Manfred Horst Director Business Development, European External Scientific Affairs, Merck Trevor Howe Scientific Director and Janssen Fellow Rod Hubbard Professor, University of York and Senior Fellow, Vernalis Uwe Huedepohl VP of R&D Project, Portfolio and Science Submission Management, MedImmune Ali Jazayeri Head of Protein Engineering, Heptares Patrick Jimonet Discovery Sourcing And Leader Global Chemical Library Team, Sanofi Guido Koch Director in Global Discovery Chemistry, Novartis Bharat Lagu Associate Director, Novartis Alastair Lawson, Senior Director of Structural Biology, UCB Andrew Leach Director of Computational Chemistry Europe, GSK Xavier Leroy Associate Director, Project Leader, Actelion Clive Long, Vice President, NBE Discovery, Boehringer Ingelheim Andreas Marzinzik Director, Exploratory Medicinal Chemistry, Novartis John Mathias Senior Director Head of Medicinal Chemistry, Inflammation & Remodelling, Pfizer Lorenz Mayr, Vice President & Global Head, Reagents & Assay Development, AstraZeneca Richard Morphy Senior Research Advisor, Eli Lilly Paul Nicklin Director, Low Molecular Weight Drug Discovery, Respiratory Diseases Area, Novartis Henning Nielsen Director, Novo Nordisk William Pennie Executive Director of Compound Safety Prediction, Pfizer Björn Peters, Director Business Development, Shire Jens Pohlmann Head of Chemistry, Basilea Huw Rees Senior Principal Scientist, Pfizer Ton Rijnders Scientific Director, TI Pharma Ulrich Schopfer Director, Integrated Lead Discovery Head, Novartis Alexander Schuhmacher Professor, Reutlingen University William Strohl VP Biologics Research, Johnson & Johnson Dominique Surleraux VP Chemistry, Idenix Atli Thorarensen, Associate Research Fellow, Pfizer Axel Vater VP Discovery, Noxxon Sjoerd Wadman VP R&D, Lanthio Christoph Wiessner Head of Discovery, Asceneuron Ian Wilson Computational Chemist, GSK Campbell Wilson Executive Business Development Director. Science & Technology Licensing, AstraZeneca Julian Woelcke Associate Director Expertise Platform Proteases, Novartis Francisca Zanoguera Head of Discovery Bioinformatics Geneva, Merck Serono

Deadline for Abstracts:			NA

Registration:			For more information and to register: http://www.drugdiscovery-summit1.com/download-agenda/
E-mail:			d.meredith@oxfordglobal.co.uk

events

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.